The biotech is putting Voxzogo, its drug for skeletal disorders, at the center of plans to grow revenue the rest of this decade and beyond.
BioMarin, having retrenched, outlines plans for growth
The biotech is putting Voxzogo, its drug for skeletal disorders, at the center of plans to grow revenue the rest of this decade and beyond.